Neuronetics Inc
NASDAQ:STIM
Neuronetics Inc
Revenue
Neuronetics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuronetics Inc
NASDAQ:STIM
|
Revenue
$74.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$17.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Neuronetics Inc
Revenue Breakdown
Breakdown by Geography
Neuronetics Inc
|
Total Revenue:
74.9m
USD
|
|
United States:
72.5m
USD
|
|
International:
2.4m
USD
|
Breakdown by Segments
Neuronetics Inc
|
Total Revenue:
74.9m
USD
|
|
Represents Information Pertaining To Medical ...:
74.9m
USD
|
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
What is Neuronetics Inc's Revenue?
Revenue
74.9m
USD
Based on the financial report for Dec 31, 2024, Neuronetics Inc's Revenue amounts to 74.9m USD.
What is Neuronetics Inc's Revenue growth rate?
Revenue CAGR 5Y
4%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Neuronetics Inc have been 11% over the past three years , 4% over the past five years .
You don't have any saved screeners yet